Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
GOSS Stock Chart & Stats
$0.34
-$0.10(-9.01%)
At close: 4:00 PM EST
$0.34
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.32 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)25.19M
Market Cap
$89.54M
Enterprise Value$253.77M
Total Cash (Recent Filing)$136.93M
Total Debt (Recent Filing)$201.97M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 12, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding234,696,270
10 Day Avg. Volume12,616,644
30 Day Avg. Volume25,191,408
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap2.83
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit5.26
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$4.40Price Target Upside1194.12% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$25.78M
Bulls Say, Bears Say
Bulls Say
Cash Preservation And RunwaySignificant workforce reductions and paused peripheral programs conserve cash to prioritize the pulmonary arterial hypertension program, extending resources to support potential NDA activities.
Clinical DifferentiationConsistent signals in higher‑risk patient subgroups and supportive long‑term extension data suggest seralutinib may produce durable, disease‑modifying benefits that differentiate it from short‑term therapies.
Regulatory ClarityA planned Type C meeting with the FDA to discuss a two‑trial NDA could determine whether a two‑study submission is acceptable, creating a clearer regulatory pathway if the agency concurs.
Bears Say
Dataset Integrity And Placebo VariabilityStructural issues in the trial dataset and high placebo variability raise doubt that regulators will accept a two‑study argument, increasing the likelihood of requests for additional data or trials.
Enrollment PauseEnrollment in the ongoing Phase 3 study was paused to assess the PROSERA outcome and plan regulator discussions, interrupting development momentum and increasing the risk of program delays.
Primary Endpoint MissThe Phase 3 PROSERA trial missed its primary endpoint due to stronger‑than‑expected placebo performance, creating substantial uncertainty about relying on that result for approval.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.32 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $89.54M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is May 12, 2026 which is in 47 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Mar 17, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.014.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.17.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 234,696,270 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went down -7.856%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.40 (1194.12% Upside)
$4.40 (1194.12% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.12%
12-Months-Change
Fundamentals
Return on Equity
264.70%
Trailing 12-Months
Asset Growth
-45.37%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Stock 12 Month Forecast
Average Price Target
$4.40
▲(1194.12% Upside)
Technical Analysis
Ownership Overview
3.94% Insiders
9.63% Mutual Funds
40.79% Other Institutional Investors
31.91% Public Companies and Individual Investors